Tranquill L[au] - Search Results

Year	Number of Results
1993	2
1994	2
1995	1
1996	3
1997	6
1998	2
2000	2
2022	0

1

Mechanisms of immunomodulation by glatiramer acetate.

Gran B, Tranquill LR, Chen M, Bielekova B, Zhou W, Dhib-Jalbut S, Martin R. Gran B, et al. Among authors: tranquill lr. Neurology. 2000 Dec 12;55(11):1704-14. doi: 10.1212/wnl.55.11.1704. Neurology. 2000. PMID: 11113226

2

Phase 1 trial of transforming growth factor beta 2 in chronic progressive MS.

Calabresi PA, Fields NS, Maloni HW, Hanham A, Carlino J, Moore J, Levin MC, Dhib-Jalbut S, Tranquill LR, Austin H, McFarland HF, Racke MK. Calabresi PA, et al. Among authors: tranquill lr. Neurology. 1998 Jul;51(1):289-92. doi: 10.1212/wnl.51.1.289. Neurology. 1998. PMID: 9674825 Clinical Trial.

3

Enhanced T cell responsiveness to citrulline-containing myelin basic protein in multiple sclerosis patients.

Tranquill LR, Cao L, Ling NC, Kalbacher H, Martin RM, Whitaker JN. Tranquill LR, et al. Mult Scler. 2000 Aug;6(4):220-5. doi: 10.1177/135245850000600402. Mult Scler. 2000. PMID: 10962541

4

Human autoreactive CD4+ T cell clones use perforin- or Fas/Fas ligand-mediated pathways for target cell lysis.

Vergelli M, Hemmer B, Muraro PA, Tranquill L, Biddison WE, Sarin A, McFarland HF, Martin R. Vergelli M, et al. Among authors: tranquill l. J Immunol. 1997 Mar 15;158(6):2756-61. J Immunol. 1997. PMID: 9058810

5

Differential activation of human autoreactive T cell clones by altered peptide ligands derived from myelin basic protein peptide (87-99).

Vergelli M, Hemmer B, Utz U, Vogt A, Kalbus M, Tranquill L, Conlon P, Ling N, Steinman L, McFarland HF, Martin R. Vergelli M, et al. Among authors: tranquill l. Eur J Immunol. 1996 Nov;26(11):2624-34. doi: 10.1002/eji.1830261113. Eur J Immunol. 1996. PMID: 8921948

6

VLA-4 expression on peripheral blood lymphocytes is downregulated after treatment of multiple sclerosis with interferon beta.

Calabresi PA, Pelfrey CM, Tranquill LR, Maloni H, McFarland HF. Calabresi PA, et al. Among authors: tranquill lr. Neurology. 1997 Oct;49(4):1111-6. doi: 10.1212/wnl.49.4.1111. Neurology. 1997. PMID: 9339698

7

T cell response to two immunodominant proteolipid protein (PLP) peptides in multiple sclerosis patients and healthy controls.

Pelfrey CM, Tranquill LR, Vogt AB, McFarland HF. Pelfrey CM, et al. Among authors: tranquill lr. Mult Scler. 1996 Apr;1(5):270-8. doi: 10.1177/135245859600100503. Mult Scler. 1996. PMID: 9345429

8

HLA restriction and TCR usage of T lymphocytes specific for a novel candidate autoantigen, X2 MBP, in multiple sclerosis.

Voskuhl RR, Robinson ED, Segal BM, Tranquill L, Camphausen K, Albert PS, Richert JR, McFarland HF. Voskuhl RR, et al. Among authors: tranquill l. J Immunol. 1994 Nov 15;153(10):4834-44. J Immunol. 1994. PMID: 7525716

9

Human T lymphocytes specific for the immunodominant 83-99 epitope of myelin basic protein: recognition of golli MBP HOG 7.

Tranquill LR, Skinner E, Campagnoni C, Vergelli M, Hemmer B, Muraro P, Martin R, McFarland HF, Campagnoni AT, Voskuhl RR. Tranquill LR, et al. J Neurosci Res. 1996 Sep 15;45(6):820-8. doi: 10.1002/(SICI)1097-4547(19960915)45:6<820::AID-JNR19>3.0.CO;2-Z. J Neurosci Res. 1996. PMID: 8892094

10

Increases in soluble VCAM-1 correlate with a decrease in MRI lesions in multiple sclerosis treated with interferon beta-1b.

Calabresi PA, Tranquill LR, Dambrosia JM, Stone LA, Maloni H, Bash CN, Frank JA, McFarland HF. Calabresi PA, et al. Among authors: tranquill lr. Ann Neurol. 1997 May;41(5):669-74. doi: 10.1002/ana.410410517. Ann Neurol. 1997. PMID: 9153530 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results